Patents Examined by Robert W. Ramsuer
  • Patent number: 6740760
    Abstract: New compounds have the formula: wherein R, R1, X and Y have the meanings described herein. Methods are set forth for synthesizing these compounds and using these compounds to treat diseases associated with amyloidosis, such as Alzheimer's disease, maturity onset diabetes mellitus, familial amyloid polyneuropathy, scrapie, and Kreuzfeld-Jacob disease.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: May 25, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Cornelia Hertel, Torsten Hoffmann, Roland Jakob-Roetne, Roger David Norcross
  • Patent number: 6737440
    Abstract: The present invention relates to novel 2,5-bis {[alkyl(or aryl)imino]aminophenyl}furans and thiophenes of the general formula in which R1, R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups; R5 is H, alkyl or aryl; R6 is H, alkyl, aryl, or NR7R8, in which R7 and R8 are each independently selected from the group consisting of H, alkyl and aryl; and X is O, S or NR9, in which R9 is H or alkyl, and to the use of such compounds.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: May 18, 2004
    Assignees: The University of North Carolina at Chapel Hill, Georgia State University Research Foundation, Inc., Duke University
    Inventors: David W. Boykin, Richard R. Tidwell, W. David Wilson, John R. Perfect, Chad F. Stephens
  • Patent number: 6737431
    Abstract: Novel benzoxazole derivatives which have a binding affinity for the human melatonin receptor and, therefore, are useful as melatonergic agents.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: May 18, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Katherine S. Takaki, Li-Qiang Sun, Graham Johnson, Stephen R. Bertenshaw, Derek Denhart, Jie Chen
  • Patent number: 6734198
    Abstract: The invention relates to compounds of formula (I) in which X represents halogen, and n represents 0, 1 or 2, to a process for their preparations and to their use as nematacides.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: May 11, 2004
    Assignee: Nihon Bayer Agrochem K.K.
    Inventors: Yukiyoshi Watanabe, Koichi Ishikawa, Yuichi Otsu, Katsuhiko Shibuya, Takahisa Abe
  • Patent number: 6730689
    Abstract: The present application describes N-[4-(1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides and derivatives thereof of, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: May 4, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Mimi L. Quan
  • Patent number: 6730690
    Abstract: Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: are selective inhibitors of the 11&bgr;-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: May 4, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Steven H. Olson, James M. Balkovec, Yuping Zhu
  • Patent number: 6727250
    Abstract: Carboxylic acid amides of general formula which inhibit telomerase and are useful for treating tumor diseases such as carcinomas, sarcomas and leukaemias. Exemplary compounds are: (1) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide, and, (2) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4,5-dimethoxy-phenyl)-amide.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: April 27, 2004
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Norbert Hauel, Henning Priepke, Klaus Damm, Andreas Schnapp
  • Patent number: 6727266
    Abstract: A compound of the formula (I): wherein: R1 is represented by the formula: wherein R4, R5, R6, R7 and R8 are monovalent radicals such as: hydrogen, halogen, optionally substituted lower alkyl, lower alkyloxy, lower alkylthio, optionally substituted amino, nitro; non-aromatic heterocyclic group, and the like with certain provisos; Y is —OH or —NHOH; R2 is hydrogen, optionally substituted lower alkyl, or optionally substituted aralkyl; R3 is halogen, hydroxy, lower alkyloxy, or lower alkylthio; (b) n is an integer from 1 to 3; its optically active substance, its prodrug, its pharmaceutically acceptable salt, and its solvate.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: April 27, 2004
    Assignee: Shionogi & Co., Ltd.
    Inventor: Fumihiko Watanabe
  • Patent number: 6727247
    Abstract: A compound of formula I and a method of treatment of diseases, related to modulation of the adenosine A2 receptor system comprising administering a compound of formula to a person in need of such treatment.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: April 27, 2004
    Assignee: Hoffman-La Roche Inc.
    Inventors: Alexander Flohr, Roland Jakob-Roetne, Roger David Norcross, Claus Riemer
  • Patent number: 6727366
    Abstract: The present invention relates generally to a novel class of imidazolidinones of Formula (I): that are useful as serine protease inhibitors, and more particularly as Hepatitis C virus NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: April 27, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Amy Qi Han, Peter W. Glunz
  • Patent number: 6727246
    Abstract: The present invention provides compounds of formula I and the use thereof for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: April 27, 2004
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler A. Antane, Ping Zhou, Yanfang Li
  • Patent number: 6727370
    Abstract: Oxydiphthalic anhydrides such as 4-oxydiphthalic anhydride are prepared by the reaction of a halophthalic anhydride with an alkali metal carbonate such as potassium carbonate in the presence of a catalyst system comprising an alkali metal bicarbonate such as potassium bicarbonate and a phase transfer catalyst, preferably a tetraarylphosphonium halide.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: April 27, 2004
    Assignee: General Electric Company
    Inventors: Daniel Joseph Brunelle, Qing Ye
  • Patent number: 6723860
    Abstract: The present invention provides a novel 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one represented by the formula (I): wherein R1 and R2 each represent a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group; R3 represents an alkyl group, a cyclo-alkyl group, an alkenyl group, an aryl group or an aralkyl group, provided that a 2-alkenyl group is excluded from the alkenyl group of R3; and R4 represents an alkyl group, an aryl group, an alkoxycarbonyl group or a cyano group, and a process for producing the same which comprises reacting 5-alkoxy-2(3H)-oxazolone with an &agr;,&bgr;-unsaturated ketone in the presence of a Lewis acid in a solvent.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: April 20, 2004
    Assignee: UBE Industries, Ltd.
    Inventors: Hiroyuki Miyata, Takashi Honma, Yasuhito Yamamoto, Kikuo Ataka
  • Patent number: 6723138
    Abstract: A process for preparing diketopyrrolopyrrole pigments comprises conducting the elementary steps of pigment synthesis (reaction and hydrolysis) in a miniaturized continuous reactor.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: April 20, 2004
    Assignee: Clariant International Ltd.
    Inventors: Uwe Nickel, Leonhard Unverdorben, Joachim Weber, Erwin Dietz, Juergen Patzlaff
  • Patent number: 6723735
    Abstract: The present invention is directed to 3-phenylimidazol[4,5-b]pyridine derivatives, that are selective ligands for GABAA receptors. These compounds are useful in the treatment and prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: April 20, 2004
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: David James Hallett, Michael Rowley
  • Patent number: 6720429
    Abstract: The present invention provides a thiocarbonylthio compound represented by formula (I) Wherein n is an integer of 0 to 3; R1 is alkyl, haloalkyl, alkenyl, aryl, alkylaryl, haloalkylaryl, arylalkyl, aminoalkyl, alkylamino, alkoxy, alkoxyaryl, alkyl sulfide, or alkylsilyl; R2 and R3 are independently H, alkyl, haloalkyl, alkenyl, aryl, alkylaryl, arylalkyl, aminoalkyl, alkylamino, alkoxy, alkyl sulfide, or alkylsilyl; R4 and R5 are independently H, alkyl, haloalkyl, alkenyl, aryl, alkylaryl, arylalkyl, aminoalkyl, alkylamino, alkoxy, alkyl sulfide, or alkylsilyl, or R4 and R5 link together with the carbon atoms to which they are attached to form a ring system; and Y is O or S. The thiocarbonylthio compound can be used in a living free radical polymerization to obtain a polymer with high conversion and low polydispersity.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: April 13, 2004
    Assignee: Industrial Technology Research Institute
    Inventors: Lizamma Mathew, Kuo-Chen Shih
  • Patent number: 6720322
    Abstract: The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: April 13, 2004
    Assignee: Actelion Pharamceuticals Ltd.
    Inventors: Martin Bolli, Christoph Boss, Martine Clozel, Walter Fischli
  • Patent number: 6720323
    Abstract: The invention related to colchinol derivatives of the formula (I): Wherein: R1, R2 and R3 are each independently hydroxy, phosphoryloxy (—OPO3H2), C1-4alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R1, R2 and R3 are C1-4alkoxy; A is —CO—, —C(O)O—, —CON(R8)— (wherein R8 is hydrogen, C1-4alkyl, C1-3alkoxyC1-3alkyl, aminoC1-3alkyl or hydroxyC1-3alkyl); a is an integer from 1 to 4 inclusive; Ra and Rb are independently selected from hydrogen, hydroxy and amino; B is —O—, —CO—, N(R9)CO—, —CON(R9)—, —N(R9)C(O)O—, —N(R9)CON(R10)—, —N(R9)SO2—, —SO2N(R9)— or a direct single blond (wherein R9 and R10 are independently selected from hydrogen, C1-4alkyl, C1-3alkoxyC1-3alkyl, aminoC1-3alkyl and hydroxyC1-3alkyl); b is 0 or an integer from 1 to 4 inclusive, (provided that when b is 0, B is a single direct bond); D is carboxy, sulpho, tetrazolyl, imidazo
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: April 13, 2004
    Assignee: Angiogene Pharmaceuticals Limited
    Inventor: Jean Claude Arnould
  • Patent number: 6720339
    Abstract: Disclosed are compounds of the formula or the pharmaceutically acceptable non-toxic salts thereof wherein: W represents substituted or unsubstituted aryl or heteroaryl; T is hydrogen, halogen, hydroxyl, amino or alkyl; X is hydrogen, hydroxy, or lower alkyl; m is 0, 1, or 2; n is 0, 1, or 2; and R3 and R4 represent substituted or unsubstituted organic residues. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors These compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: April 13, 2004
    Assignee: Neurogen Corporation
    Inventors: Pamela Albaugh, Gang Liu, Alan Hutchison
  • Patent number: 6716980
    Abstract: The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA) X2—CH2—C•H(OH)—CH2—NH—CO—RN   (VIIIA) and processes for production of pharmacologically useful oxazolidinones.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: April 6, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventor: Bruce Allen Pearlman